文献速递膀胱癌与上尿路尿路上皮癌

纵向肿瘤知情循环肿瘤DNA状态预测根治性膀胱切除术患者的疾病分期上调与不良预后

Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy.
PubMed 文献 · Eur Urol Oncol · 2024-03-22

该研究纳入2021至2023年接受根治性膀胱切除术的112例膀胱癌患者,术前术后行肿瘤知情循环肿瘤DNA检测。术前可检测到ctDNA与较差的无复因子生存相关,并与淋巴结病变及局部晚期疾病风险升高相关;微小残留病灶窗口可检测到ctDNA可预测疾病复发。

要点

  • 术前可检测到ctDNA与较差的无复发生存相关(log-rank p < 0.0001)。
  • 术前可检测到ctDNA与淋巴结病变风险升高相关(比值比5.4,95%CI 1.9-18.2;p=0.003)。
  • 微小残留病灶窗口可检测到ctDNA可预测疾病复发(风险比9.9,95%CI 2.6-37;p<0.001)。

核心结论

  • 根治性膀胱切除术术前可检测到ctDNA可预测膀胱癌患者的淋巴结受累、局部晚期疾病及疾病复发。
  • ctDNA状态有望改善临床分期并增强现有决策工具。

研究设计与样本

  • 分析2021至2023年接受根治性膀胱切除术并在术前术后行前瞻性肿瘤知情ctDNA分析的患者数据,共纳入112例。
  • 采用Kaplan-Meier法评估无复发生存,采用Cox比例风险模型评估疾病复发预测因素,采用单变量和多变量回归分析评估术前可检测ctDNA相关的病理结局。

主要发现

  • 中位随访8个月(四分位距4-13)。
  • 术前可检测到ctDNA者59例(53%),与较差的无复发生存相关(log-rank p < 0.0001)。
  • 无论临床分期(<cT2 vs ≥cT2)及是否接受新辅助治疗,术前可检测到ctDNA均与不良结局相关。
  • 多变量分析显示术前可检测到ctDNA与淋巴结病变风险升高相关(比值比5.4,95%CI 1.9-18.2;p=0.003),与局部晚期疾病风险升高相关(比值比3.6,95%CI 1.5-9;p=0.005)。
  • Cox回归分析显示术前可检测到ctDNA(风险比4.5,95%CI 1-19;p=0.04)及微小残留病灶窗口可检测到ctDNA(风险比9.9,95%CI 2.6-37;p<0.001)可预测疾病复发。

临床怎么用

  • 作者认为ctDNA状态有望改善临床分期并增强当前决策工具。
  • 作者指出该检测的使用可帮助临床医生和患者决策,以实现该疾病的最佳个体化治疗。

局限性

  • 中位随访8个月(四分位距4-13)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Decision-making on the use of neoadjuvant and adjuvant treatment for patients with bladder cancer undergoing radical cystectomy (RC) currently depends on assessment of clinical and pathological features, which lack sensitivity. Circulating tumor DNA (ctDNA) has emerged as a possible novel prognostic biomarker in the field. Our aim was to assess whether ctDNA status before RC is predictive of pathological and oncological outcomes. We also evaluated the dynamic changes in ctDNA status after RC in relation to recurrence-free survival (RFS). METHODS: We analyzed data for patients who underwent RC during 2021-2023 for whom prospective tumor-informed ctDNA analyses were conducted before and after RC. RFS was evaluated using the Kaplan-Meier method. Predictors for disease recurrence were assessed using Cox proportional-hazards models. Pathological outcomes associated with detectable ctDNA before RC were assessed in univariable and multivariable regression analyses. KEY FINDINGS AND LIMITATIONS: We included 112 patients in the analysis. Median follow-up was 8 mo (interquartile range 4-13). ctDNA was detected before RC in 59 patients (53%) and was associated with poor RFS (log-rank p < 0.0001). Detectable ctDNA before RC was associated with poor outcomes regardless of clinical stage (<cT2 vs ≥cT2) and receipt of neoadjuvant therapy. Multivariable analyses revealed that detectable ctDNA before RC was associated with a higher risk of nodal disease (odds ratio 5.4, 95% confidence interval [CI] 1.9-18.2; p = 0.003) and locally advanced disease (odds ratio 3.6, 95% CI 1.5-9; p = 0.005). Cox regression analyses showed that detectable ctDNA before RC (hazard ratio 4.5, 95% CI 1-19; p = 0.04) and detectable ctDNA at the minimal residual disease window (hazard ratio 9.9, 95% CI 2.6-37; p < 0.001) were predictive of disease recurrence. CONCLUSIONS AND CLINICAL IMPLICATIONS: Detectable ctDNA before definitive therapy with RC is predictive of nodal involvement, locally advanced disease, and disease recurrence in patients with bladder cancer. ctDNA status holds promise for improving clinical staging and augmenting current decision-making tools. PATIENT SUMMARY: We found that for patients with bladder cancer undergoing radical cystectomy, a test to show the presence of tumor DNA in blood before surgery was able to predict the risk of disease relapse and adverse pathology. Use of this assay could help in decision-making by clinicians and patients for optimal personalized treatment of this disease.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ben-David R, Tillu N, Cumarasamy S, et al. Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy. Eur Urol Oncol. 2024. PMID: 38521660. doi:10.1016/j.euo.2024.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。